Johns Hopkins Drug Discovery - John Hopkins University
The Johns Hopkins Drug Discovery Program continues to work with the researchers across Johns Hopkins to research and develop tomorrow’s therapeutics for a wide range of human disorders.
Johns Hopkins, Drug Discovery, Transforming academic translational research
2
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-2,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive
Johns Hopkins University Drug Discovery

Transforming academic
translational research

Expertise in drug
discovery research

Developing for the future

What’s New?

First-in-human Phase 1/2a clinical trial initiated for JHDD-invented glutamine antagonist for the treatment of solid tumors

JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]

JHDD awarded a Crohn’s and Colitis Foundation grant to develop a novel treatment for IBD

JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain

Partnership Awards $3 Million In Grants For Promising New Treatments In Alzheimer’s And Related Dementias

JHDD start-up Dracen Pharmaceuticals receives $40.5 million to develop Glutamine Antagonists

Building innovative partnerships

Johns Hopkins University Drug Discovery - JHU Drug Discovery

Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.

Interested in Working With Us?

We welcome opportunities to discuss how we can work together in a drug discovery collaboration.

 

lowgo_bottom